Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Microbiome and Metabolome Integrated Analysis: Exploring Potential Diagnostic Approaches for Parkinson’s Disease Using Tongue Coating Samples

ABSTRACT:

Parkinson's disease (PD) is a prevalent neurodegenerative disorder with complex pathogenesis and limited treatment options. The current reliance on clinical evaluation for diagnosis, due to the absence of reliable non-invasive methods, presents significant challenges. Traditional diagnostic approaches, including cerebrospinal fluid (CSF) or blood sampling, are invasive, pose risks of infection, are costly, and often require complex procedures. Tongue coating sampling offers a non-invasive, cost-effective and repeatable alternative, showing promise for early detection and monitoring of PD. This study explores the feasibility of using tongue coating samples as a diagnostic tool for PD through microbiome analysis, with metabolomics data providing additional context and validation via machine learning models.

INSTRUMENT(S): Liquid Chromatography MS - positive - reverse phase

PROVIDER: MTBLS12679 | MetaboLights | 2025-07-05

REPOSITORIES: MetaboLights

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	a_MTBLS12679_LC-MS_positive_reverse-phase_metabolite_profiling.txt	Txt
	i_Investigation.txt	Txt
	m_MTBLS12679_LC-MS_positive_reverse-phase_metabolite_profiling_v2_maf.tsv	Tabular
	s_MTBLS12679.txt	Txt

Items per page:

1 - 4 of 4

Similar Datasets

mRNA expression profiling of mitochondrial subunits in subjects with Parkinson’s disease

Project description:Introduction: Parkinson's disease (PD), typically developing between the ages of 55 and 65 years, is a common neurodegenerative disorder caused by a progressive loss of dopaminergic neurons due to the accumulation of α-synuclein in the substantia nigra. Mitochondria are known to play a key role in cell respiratory function and bioenergetic. Indeed, mitochondrial dysfunction causes an insufficient energy production required to satisfy the needs of several organs, especially the nervous system. Material and methods: The present study explored the mRNA expression of mitochondrial DNA (mtDNA) encoded respiratory chain (RC) subunits in PD patients by using the next generation sequencing analysis (NGS) and the quantitative real-time PCR (qRT-PCR) assay for the confirmation of the NGS results. Results: All tested mitochondrial RC subunits was significantly over-expressed in subjects with PD compared to normal controls . In qRT-PCR the mean expression of all mitochondrial subunits had an expression level of at least 7 times compared to controls. Conclusion: The over-expression of mitochondrial subunits in PD subjects might be secondary to a degeneration-related alteration of the mitochondrial structure or dynamics or to the occurrence of a compensatory mechanism. The study of specific mRNA by peripheral blood mononuclear cells (PBMCs) may provide a better diagnostic frame to early detect PD cases.

2022-01-01 | E-MTAB-9950 | biostudies-arrayexpress

Proteome Profiling of Cerebrospinal Fluid reveals novel biomarker candidates for Parkinson’s disease

Project description:Parkinson's disease (PD) is a growing burden worldwide, and despite ongoing efforts to find reliable biomarkers for early and differential diagnosis, prognosis and disease monitoring, there is no biofluid biomarker used in clinical routine to date. Cerebrospinal fluid (CSF) is collected often and should closely reflect structural and functional alterations in PD patients' brains. Here we describe a scalable and sensitive mass spectrometry (MS)-based proteomics workflow for CSF proteome profiling to find specific biomarkers and identify disease-related changes in CSF protein levels in PD. From two independent cohorts consisting of more than 200 individuals, our workflow reproducibly quantified over 1,700 proteins from minimal sample amounts. Combined with machine learning, this identified a group of several proteins, including OMD, CD44, VGF, PRL, and MAN2B1 that were altered in PD patients or significantly correlate with clinical scores, indicative of disease progression. Interestingly, we uncovered signatures of enhanced neuroinflammation in patients with familial PD (LRRK2 G2019S carriers) as indicated by increased levels of CTSS, PLD4, HLA-DRA, HLA-DRB1, and HLA-DPA1. A comparison with urinary proteome changes in PD patients revealed a large overlap in protein composition PD-associated changes in these body fluids, including lysosomal factors like CTSS. Our results validate MS-based proteomics of CSF as a valuable strategy for biomarker discovery and patient stratification in a neurodegenerative disease like PD. Consistent proteomic signatures across two independent CSF cohorts and previously acquired urinary proteome profiles open up new avenues to improve our understanding of PD pathogenesis.

2022-06-01 | PXD026491 | Pride

1H-NMR-based metabolomic analysis identifies disrupted glutamate metabolism as distinct serum signature in Parkinson’s disease patients

Project description:Using High-Performance Liquid Chromatography, we recently demonstrated a complex dysregulation of the glutamate NMDA receptor-stimulating amino acids in the brain, CSF and serum of Parkinson’s disease (PD) experimental models and patients. Here, we investigate the serum metabolomic profile in the same PD patients and healthy controls (HC) cohorts through an untargeted 1H-Nuclear Magnetic Resonance approach. We found that serum Glutamate levels discriminated PD and HC groups with high diagnostic accuracy.

2024-11-08 | MTBLS10958 | MetaboLights

Urinary proteome profiling in Parkinson’s disease

Project description:The prevalence of Parkinson's disease (PD) is increasing but the development of novel treatment strategies and therapeutics altering the course of the disease would benefit from specific, sensitive and non-invasive biomarkers to detect PD early. Here, we describe a scalable and sensitive proteomics workflow for urinary proteome profiling by combining high-throughput sample preparation with state-of-the-art mass spectrometry (MS)-based proteomics. Our workflow enabled the reproducible quantification of more than 2,000 proteins in more than 200 urine samples using minimal volumes from two independent cohorts. The urinary proteome was significantly different between PD patients and healthy controls as well as between LRRK2 G2019S carriers and non-carriers in both cohorts. Interestingly, our data revealed lysosomal dysregulation in individuals with the LRRK2 G2019S mutation. Machine learning on the urinary proteome data alone classified mutation status and especially disease manifestation in mutation carriers remarkably well (ROC AUCs 0.87 and 0.94, respectively), identifying VGF, ENPEP and other PD-associated proteins as the most discriminating features. Our results validate urinary proteomics as a valuable strategy for biomarker discovery and patient stratification in PD.

2020-11-24 | PXD020722 | Pride

A Next-Generation Sequencing Study in a Cohort of Patients with Parkinson’s Disease

Project description:Background: Parkinson’s disease (PD) is a multisystem and multifactorial disorder. Therefore, the application of modern genetic techniques may assist in unraveling its complex pathophysiology. Methods: We conducted a clinical-demographic evaluation of 126 patients with PD, all of whom were Caucasian and of Sicilian ancestry. DNA was extracted from peripheral blood for each patient, followed by sequencing using a Next-Generation Sequencing system. This system was based on a custom gene panel comprising 162 genes. The sample underwent further filtering, taking into account allele frequencies of genetic variants, their presence in the Human Gene Mutation Database, and their association in the literature with PD or other movement/neurodegenerative disorders. Results: The largest number of variants was identified in the leucine-rich repeat kinase 2 (LRRK2) gene. However, variants in other genes, such as acid beta-glucosidase (GBA), DNA polymerase gamma, catalytic subunit (POLG), and parkin RBR E3 ubiquitin protein ligase (PRKN), were also discovered. Interestingly, some of these variants had not been previously associated with PD. Conclusions: Enhancing our understanding of the genetic basis of PD and identifying new variants possibly linked to the disease will contribute to improved diagnostic accuracy, therapeutic developments, and prognostic insights for affected individuals.

2024-10-14 | E-MTAB-13523 | biostudies-arrayexpress

Epigenetic modification, as a distinctive therapeutic molecule for Parkinson’s disease gene therapy.

Project description:Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons (DN) in the substantia nigra and disruption of cellular maintenance. Here, we demonstrate that NDST3-mediated epigenetic reprogramming halts neuronal degeneration and restores motor function in an animal model of PD.

2025-11-30 | GSE308116 | GEO

Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles

Project description:Parkinson's Disease (PD) and Non-Demented Control (NDC) human sera were probed onto human protein microarrays in order to identify differentially expressed autoantibody biomarkers that could be used as diagnostic indicators. In the study presented here, 29 PD and 40 NDC human serum samples were probed onto human protein microarrays in order to identify differentially expressed autoantibodies. Microarray data was analyzed using several statistical significance algorithms, and autoantibodies that demonstrated significant group prevelance were selected as biomarkers of disease. Prediction classification analysis tested the diagnostic efficacy of the identified biomarkers; and differentiation of PD samples from other neurodegeneratively-diseased and non-neurodegeneratively-diseased controls (Alzheimer's disease, multiple sclerosis, and breast cancer) confirmed their specificity.

2012-02-27 | E-GEOD-29654 | biostudies-arrayexpress

circRNAs microarray analysis in plasma of Parkinson’s Disease

Project description:Parkinson's disease (PD) is a chronic and progressive degenerative disease of the central nervous system. Degenerative neuropathy can occur in patients with PD even before typical clinical symptoms appear in the preclinical stage. Therefore, if the early diagnosis of degenerative diseases can be timely and the correlation with the disease progression can be explored, the disease progression will be slowed down and the quality of life of patients will be improved. In this study, the circRNA microarray was employed to screen the dysregulated circRNA in plasma samples of PD

2023-05-01 | GSE174052 | GEO

Differential expression of gut miRNAs in idiopathic Parkinson's disease

Project description:In the present work, we aimed to investigate the expression of microRNAs (miRNAs) in routine colonic biopsies obtained from patients with idiopathic Parkinson's disease (iPD) and to address their value as a diagnostic biomarker for PD and their mechanistic contribution to PD onset and progression.

2021-07-14 | GSE145814 | GEO

Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles

2012-02-27 | GSE29654 | GEO